-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 29, the Daiichi Sankyo TROP2 antibody-conjugated drug DS-1062a (Dato-DXd, datopotamab deruxtecan) clinical application was accepted by the State Food and Drug Administration
DS-1062a is developed using Daiichi Sankyo's proprietary DXd ADC technology.
At the ASCO conference in June 2021, Daiichi Sankyo and AstraZeneca announced the updated data of DS-1062a in the treatment of advanced or metastatic NSCLL and the phase I trial TROPION-PanTumor01 data of metastatic triple-negative breast cancer (TNBC)
As of January 8, 2021, the ORR of DS-1062a 4 mg, 6 mg, and 8 mg dose groups in NSCLC patients were 24%, 26%, and 24%, respectively; PFS were 4.
The efficacy of DS-1062a in 21 cases of pretreatment TNBC patients can be evaluated.
The development of DS-1062a for NSCLC is currently in phase III clinical phase, and a new phase I cohort study for HR+/HER2- breast cancer patients has also been opened
DS-1062a is one of the three major ADC assets in the Daiichi Sankyo Oncology pipeline and one of the most advanced projects in AstraZeneca's ADC scientific platform
AstraZeneca reached cooperation with Daiichi Sankyo at a total value of US$6.
